In 2020, Teva committed to launch eight access to medicines programs by 2025 to provide treatments to underserved populations worldwide through customized, localized models—and we achieved this target in early 2024. We partner with trusted organizations that know these communities, are familiar with the local health systems, understand patients’ treatment plans and work directly with healthcare providers to implement those plans.

We have also committed to increasing regulatory submissions for medicines in low- and middle-income countries in key therapeutic areas, including cardiovascular diseases, adult and pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care. This target is tied to our sustainability-linked bonds (SLBs), holding us accountable. Teva was the first pharmaceutical company to issue a SLB tied to both access to medicines and environmental targets.

Teva has expanded its approach to further address other factors impacting health, including through health systems strengthening and capacity building to support underserved populations.